Corporate Magazine 2012 - Boehringer Ingelheim

usiness year 2012 key aspects 2012Boehringer Ingelheim will also in the future face up to the challenges of dynamicallychanging healthcare systems. The heightened cost pressure in healthcare systemshas led to questions in the political and social world as to whether new medicines canbe afforded within the framework of reduced health budgets, even when they aresuperior to conventional therapies. The company could already feel this developmentwith the initial launch of pradaxa® and, most of all, with trajenta® in Germany.But we will continue to focus on further increases in efficiency by employing thelatest technology, as well as reducing complexity, in order to ensure BoehringerIngelheim’s competitiveness. Building up a global shared service center in Ingelheim,Germany, will progress the globalisation and standardisation of content, processesand systems. The operation and steering of the company will hereby be more efficientand more flexible.We have always been committed to Germany as location. Germany is the central locationof this global company Boehringer Ingelheim where we achieve only 7% of ourturnover, but where we have created jobs for 28% of our employees. A country inwhich we make 50% of our total investments, and in which we invest a research anddevelopment share of more than 50% for new, innovative medications. In Germanywe also pay over 77% of our taxes.As a research-driven company, we can only invest in the research and development ofnew, innovative medicines, if the corporate risk and innovations are rewarded at a riskadequatelevel. Public sector cost-benefit calculations, primarily in Germany, solelybased on cost control, are short-sighted with regard to sustainable improvement of thehealthcare system.OutlookWe are convinced, on the basis of our established product portfolio and the successfullaunches of new products from our own research and development expected for2013 and beyond will sustainably reinforce and expand our position in the globalhuman and veterinary pharmaceuticals market.Key aspects 201215